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Tumor necrosis factor a ( TNF-a) binding to the TNF receptor ( TNFR) poten-
tially initiates apoptosis and activates the transcription factor nuclear factor
kappa B (NF-kB), which suppresses apoptosis by an unknown mechanism. The
activation of NF-kB was found to block the activation of caspase-8. TRAF1
( TNFR-associated factor 1), TRAF2, and the inhibitor-of-apoptosis (IAP) pro-
teins c-IAP1 and c-IAP2 were identified as gene targets of NF-kB transcriptional
activity. In cells in which NF-kB was inactive, all of these proteins were required
to fully suppress TNF-induced apoptosis, whereas c-IAP1 and c-IAP2 were
sufficient to suppress etoposide-induced apoptosis. Thus, NF-kB activates a
group of gene products that function cooperatively at the earliest checkpoint
to suppress TNF-a–mediated apoptosis and that function more distally to
suppress genotoxic agent–mediated apoptosis.
TNF engagement of TNFR1 leads to the re-
cruitment of TRADD (TNFR1-associated
death domain protein) and RIP (receptor-in-
teracting protein) to the receptor complex (1).
TRADD interacts with FADD (Fas-associat-
ed death domain protein; also called MORT1,
mediator of receptor-induced toxicity) to ini-
tiate the death pathway and recruits several
proteins such as TRAF1, TRAF2, and RIP to
transduce TNF signaling pathways such as
the activation of the transcription factor NF-
kB (1, 2). The interaction of caspase-8 (FLICE,
FADD-like ICE; also called MACH, Mort1-
associated CED-3 homolog) with the death
domain protein FADD on TNFR1 initiates
the caspase cascade (3). Caspase-8 is activat-
ed by oligomerization-induced processing in
vivo and in vitro (4). Thus, caspase-8 is at the
apex of the caspase pathway and links death
domain protein signaling and caspase activa-
tion. Little is known about the regulatory
events that render cells resistant to pro-
grammed cell death. The transcription factor
NF-kB (2) inhibits the apoptotic response
induced by TNF and other stimuli (5, 6 ). We
now identify a mechanism to explain the ability
of NF-kB to suppress apoptosis in response to
TNF signaling or other apoptotic agents, there-
by defining a mechanism to explain how cells
can resist an apoptotic response.
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Fig. 1. The activation of caspases is inhibited in
HT1080I cells but not in HT1080V cells after
TNF treatment. (A) NF-kB blocks caspase acti-
vation. HT1080V and HT1080I cells were treat-
ed with TNF-a at 100 ng/ml for the indicated
time periods. Cells were lysed in hypotonic
buffer [20 mM tris-Hcl (pH 7.5), 1 mM EDTA,
100 mM phenylmethylsulfonyl fluoride, aproto-
nin (2 mg/ml), pepstatin (2 mg/ml), and leupep-
tin (2 mg/ml)], and the supernatants were in-
cubated with DEVD-pNA (100 mM) and YVAD-
pNA (100 mM) substrate. The reaction was
measured with a plate reader at 405-nm wave-
length. }, DEVD-specific caspase activity in
HT1080I cells; h, DEVD-specific caspase activ-
ity in HT1080V cells; {, YVAD-specific activity
in HT1080I cells; ■, YVAD-specific caspase ac-
tivity in HT1080V cells. The results represent
the average value from two independent exper-
iments. (B) NF-kB activation blocks cyto-
chrome c release from mitochondria. HT1080I
and HT1080V cells were treated with TNF-a (100 ng/ml) for the indicated times.
Cytosolic proteins were extracted and separated by 10% SDS–polyacrylamide gel
electrophoresis. The blot was probed with monoclonal antibody to cytochrome c
(1:1000). For detecting Bcl-2 and Bcl-xL, whole-cell extracts were prepared and
immunoblotted with antibodies to Bcl-2 or Bcl-xL. Molecular mass is given at right in
kilodaltons. (C) The processing of caspase-8 in response to TNF-a is inhibited by NF-kB
activation. Cells were treated with TNF-a (100 ng/ml) for the indicated time periods.
Whole-cell extracts (60 mg) were probed with antibody to caspase-8 (1:1000). For the
internal control, the same extracts were also probed with antibody to tubulin (a-
tubulin) (1:2000). (D) Caspase-8 protease activity is inhibited by NF-kB activation.
Cells were treated with TNF-a (10 ng/ml) for 8 hours, and cytosolic extracts were
prepared according to manufacturer’s protocol (Chemicon). Three hundred micrograms
of protein was incubated with IETD-pNA substrate. The reaction was measured with a
plate reader at 405-nm wavelength. Solid bar, untreated control; hatched bar, treated
with TNF-a. The results represent the average value from two independent experiments.
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The HT1080 fibrosarcoma cell line
(HT1080I) expresses a modified, super-re-
pressor form of the NF-kB inhibitor IkBa
that cannot be phosphorylated by the recently
identified IkB kinases (7). This cell line, but
not a control cell line, inhibits NF-kB nuclear
function (5). Inhibition of NF-kB activation
renders the HT1080I cells sensitive to TNF
killing (5). The caspase family of proteins
controls apoptosis induced by multiple stim-
uli such as Fas ligand and TNF (8). We
investigated whether NF-kB inhibits TNF-
mediated apoptosis through modulation of
the caspase cascade. A known inhibitor of
caspase-3, -7, and -8, DEVD (Z-Asp-Glu-
Val-Asp-fluoromethylketone), and a broad
spectrum caspase inhibitor, VAD (Z-Val-
Ala-Asp-fluoromethylketone), blocked TNF-
induced histone-associated DNA fragmenta-
tion in the HT1080I line, as determined by
enzyme-linked immunosorbent assay (ELISA)
(9). Similar results were obtained with embry-
onic fibroblasts from RelA/p65-null (p652/2)
mice (9). As expected, TNF did not induce
apoptosis in the parental HT1080V line or in
wild-type embryonic fibroblasts (9). An in vitro
substrate assay showed that DEVD-specific
caspase activity was induced in the HT1080I
line after TNF treatment, but not in the
HT1080V line control (Fig. 1A). Thus, DEVD-
specific caspases participate in TNF-mediated
apoptosis when NF-kB is inhibited.
Caspase-3 (CPP32) is a critical down-
stream protease in the caspase cascade (10),
responsible for cleavage of important sub-
strates such as poly(adenosine diphosphate–
ribose) polymerase (PARP) (11) and DNA
fragmentation factor–45 [DFF-45; also called
inhibitor of caspase-activated deoxyribonu-
clease, ICAD] (12). The addition of TNF to
HT1080I cells resulted in the cleavage of the
caspase-3 precursor within 5 hours, whereas
caspase-3 proenzyme remained unchanged in
the control HT1080V cells (9). The caspase
substrates PARP and DFF-45 were almost
totally cleaved after 8 hours of TNF treatment
in the HT1080I line, but not in the HT1080V
control cells (9). Cytochrome c is released
from mitochondria during apoptosis and is a
coactivator of caspase-3 (13). The antiapop-
totic functions of Bcl-2 and Bcl-xL involve
the inhibition of cytochrome c release from
mitochondria (14). Cytochrome c was re-
leased from mitochondria into the cytoplasm
after a 4-hour TNF stimulation of HT1080I,
but not HT1080V cells (Fig. 1B). Cyto-
chrome c oxidase II was not detected in these
extracts (9); thus, release was not due to
nonspecific effects. NF-kB may, therefore,
regulate Bcl-2 and Bcl-xL proteins. However,
the amount of Bcl-2 and Bcl-xL remained
unchanged after TNF treatment in both
HT1080V and HT1080I cells (Fig. 1B).
Thus, NF-kB controls an antiapoptotic mech-
anism upstream of the proteolytic activation
of caspase-3 and upstream of mitochondria.
We examined whether NF-kB blocked
apoptotic signaling directly at the activation of
caspase-8, the apical caspase. In contrast with
vector control cells, HT1080I processed
caspase-8 within 4 hours of TNF addition (Fig.
1C), preceding the activation of caspase-3. The
caspase-8 antibody we used did not detect the
active subunit of caspase-8, but a specific in-
hibitor of caspase-8, IETD, inhibited TNF-me-
diated apoptosis and indicated that caspase-8
was activated by TNF in HT1080I cells (9).
Both TRADD and FADD levels remained con-
stant in HT1080I and HT1080V cells over the
time course of the experiment (9). Additionally,
an in vitro assay showed that caspase-8 protease
activity was substantially induced by TNF-a
only in the HT1080I cells (Fig. 1D). Thus,
NF-kB activation suppressed the initiation of
caspase activation by blocking the activation of
caspase-8.
The inhibitor-of-apoptosis (c-IAP) proteins
suppress caspase-1–induced apoptosis (15) and
associate with TNFR1 (16). TRAF1 and
TRAF2 associate with TNFR1 and control sig-
nal transduction pathways (1). The mRNAs for
TRAF1 and c-IAP2 were essentially unex-
pressed in HT1080I cells but were induced by
TNF in HT1080V cells (Fig. 2), indicating that
Fig. 2. TRAFs and c-IAPs are induced by TNF
through activation of NF-kB. HT1080V and
HT1080I cells were treated with TNF (20 ng/ml)
with or without 25 mM VAD (to prevent the
onset of apoptosis in HT1080I cells). Total RNA
was extracted with the RNeasy kit (QIAGEN). The
ribonuclease (RNase) protection assay was per-
formed according to the supplier’s instructions
(PharMingen, San Diego, California). Briefly, hu-
man apoptosis template set hAPO-5 was labeled
with [a-32P]uridine triphosphate. RNA (10 mg),
and 8 3 105 cpm of labeled probes were used for
hybridization. After RNase treatments, the pro-
tected probes were resolved on a 5% urea-poly-
acrylamide-bis-acrylamide gel. Lanes 1 and 7, 2
and 8, 3 and 9, and 5 and 11 represent RNAs from
cells treated with TNF-a for 0, 0.5, 1, and 4 hours,
respectively. Lanes 4 and 10 and 6 and 12 were
treated with the caspase inhibitor VAD (20 mM)
for 1 and 4 hours, respectively. Lanes 1 to 6
represent RNA from HT1080V cells, and lanes 7
to 12 represent RNA from HT1080I cells. The
nomenclature is from the supplier’s kit. hTRPM2
stands for human testosterone–repressed pros-
tate message–2, hCRAF for TRAF3, and hCART for
TRAF4.
Fig. 3. c-IAP1 and c-IAP2 inhibit etoposide-
induced apoptosis but not TNF-induced apo-
ptosis under NF-kB–null conditions. (A) The
detection of stable HT1080I transfectants ex-
pressing c-IAP1 and c-IAP2. HT1080I cells were
transfected with pcDNA3-myc-c-IAP1 and
pcDNA3-myc-c-IAP2 and selected with G418
(600 mg/ml). The clones were analyzed by
monoclonal antibody to c-myc epitope
(1:1000). Clones IAP2 and IAP16 express both
c-IAP1 and c-IAP2, clones IAP18 and IAP27
express c-IAP1, and clone IAP7 expresses c-
IAP2. (B) c-IAP1 and c-IAP2 inhibit etoposide-
induced apoptosis but not TNF-induced apo-
ptosis under NF-kB–null conditions. The stable
cell clones described in (A) and control cells
were treated with 50 mM etoposide or TNF-a
(100 ng/ml), respectively, for 16 hours. The
supernatants were collected and measured by cell death ELISA as described in Fig. 1A to measure
apoptosis. OD405 nm, absorbance at 405 nm. (C) TNF and etoposide differentially induce the
processing of caspase-3 in HT1080I (I) cells expressing c-IAP1 and c-IAP2 (IIAP). Clone IAP2
described in (A) was used. Lanes 1 and 5, 2 and 6, and 3 and 7 represent cells treated with etoposide
for 0, 4, and 8 hours, respectively. Lanes 4 and 8 represent cells treated with TNF-a for 8 hours.
The processing of caspase-3 was detected by protein immunoblot with monoclonal antibody to
caspase-3 (1:1000).
R E P O R T S










NF-kB activity controls the expression of
these genes. Additionally, TRAF2 and c-IAP1
mRNAs were induced in HT1080V cells but
had a reduced, basal expression in HT1080I
cells (Fig. 2), indicating that NF-kB activation
was also required for full induction of these
genes. Virtually identical results were obtained
in other cell types when NF-kB was inhibited
(9). Thus, our data indicate that NF-kB controls
the expression of TRAF1 and TRAF2 and c-
IAP1 and c-IAP2.
c-IAP1 and c-IAP2 specifically inhibit the
active forms of caspase-3 and -7 and also
block the etoposide-induced processing of
caspase-3 (17). c-IAP2 is activated by NF-kB
but cannot inhibit TNF-mediated apoptosis in
cells in which NF-kB is inhibited (18). v-Rel,
the viral homolog of the NF-kB family mem-
ber c-Rel, induces expression of an avian
form of IAP1 (19). To compare the inhibitory
potential of c-IAP1 and c-IAP2 relative to
TNF- and etoposide-induced apoptosis, we
established stable HT1080I cell lines that ex-
press c-IAP1, c-IAP2, or both (Fig. 3A).
Some chemotherapeutic compounds activate
NF-kB, and inhibition of NF-kB renders cells
sensitive to these drugs (5). Etoposide acti-
vated NF-kB in HT1080V cells but not in
HT1080I cells; activation of NF-kB inhibited
the processing of caspase-3 and delayed cell
death in response to etoposide (9). Expres-
sion of c-IAP1, c-IAP2, or both blocked the
etoposide-induced apoptosis in HT1080I
cells during the 16-hour time course (Fig.
3B). However, these stable transfectants were
still susceptible to TNF-induced apoptosis
(Fig. 3B). The etoposide-induced processing
of caspase-3 was partially inhibited in the
HT1080I cells expressing c-IAP1 and c-IAP2
as compared with the parental HT1080I cells
(Fig. 3C). The TNF-induced processing of
caspase-3 was not suppressed in the clone
expressing c-IAP1 and c-IAP2 (Fig. 3C).
Transient expression of TRAF1, TRAF2,
or both also had no suppressive effect on
TNF-a–induced apoptosis in HT1080I cells
(9). Therefore, HT1080I cells stably express-
ing different combinations of the TRAF and
c-IAP proteins (Fig. 4A) were tested for their
ability to suppress TNF-a–induced cell
death. These cells expressed equivalent levels
of TNFR1 (9). Expression of TRAF1 and
c-IAP2 was sufficient to partially inhibit cell
death (Fig. 4B) and to suppress caspase-8
activation (Fig. 4C). However, the expression
of TRAF1 with c-IAP1 and c-IAP2 or the
expression of TRAF1 and TRAF2 with c-
IAP1 and c-IAP2 substantially enhanced the
antiapoptotic response (Fig. 4B) and the sup-
pression of the caspase-8 activity (Fig. 4C).
Transient expression assays with the LacZ
expression vector and with expression vec-
tors for TRAF1 and TRAF2 and c-IAP1 and
c-IAP2 were performed in embryonic fibro-
blasts from p652/2 animals. The expression
of the inducible TRAF and c-IAP proteins
from the appropriate expression vectors was
confirmed by protein immunoblot (9). The
individual expression of TRAF1, TRAF2, c-
IAP1, or c-IAP2 had little or no protective
function on TNF-induced apoptosis in p65-
null embryonic fibroblasts (Fig. 4D). Coex-
pression of c-IAP1, c-IAP2, TRAF1, and
TRAF2 protected the cells from TNF-a–in-
duced killing. However, coexpression of c-
IAP1 and c-IAP2 with another TRAF
(TRAF3) could not suppress cell death in-
duced by TNF-a (Fig. 4D). As a positive
control, the expression of the FADD domi-
nant negative construct inhibited TNF-in-
duced apoptosis. Thus, our data indicate that
the NF-kB–controlled expression of TRAF1
and TRAF2 along with c-IAP1 and c-IAP2
provides maximum protection against TNF-
induced apoptosis.
We show here that NF-kB activation
serves as a primary mechanism to protect
cells against an apoptotic stimulus such as
TNF. In the case of TNF, the activation of
TRAF1 and TRAF2 and c-IAP1 and c-IAP2
functions to suppress apoptosis at the level of
caspase-8. Consistent with our data, it has
been shown that cells from TRAF2-null mice
are more susceptible to killing induced by
TNF plus cycloheximide (20) and that
Fig. 4. NF-kB–induced products, c-IAP1 and c-IAP2 and
TRAF1 and TRAF2, cooperatively protect against TNF-medi-
ated apoptosis in an NF-kB–null background. (A) The detec-
tion of stable HT1080I transfectants expressing c-IAP1 and
c-IAP2. HT1080I cells were cotransfected with pcDNA3-
myc-c-IAP1, pcDNA3-myc-c-IAP2, pRK5-flag-TRAF1, and
pRK5-flag-TRAF2 and selected with G418 (600 mg/ml). The
clones were analyzed by monoclonal antibodies to myc and
flag epitope. Lane 1 shows a clone expressing TRAF1, TRAF2,
c-IAP1, and c-IAP2; lane 2 shows a clone expressing TRAF1
and c-IAP2, and lane 3 shows a clone expressing TRAF1,
c-IAP1, and c-IAP2. The top panel is a lighter exposure of the
middle panel. (B) TRAFs and c-IAPs inhibit TNF-a–induced
apoptosis under NF-kB–inhibited conditions. The stable cell
clones described in (A) and control cells were treated with
TNF-a (10 ng/ml) for 8 hours. The supernatants were collected and measured by cell death ELISA
as described in Fig. 3B to measure apoptosis. The results represent the mean value from three
independent experiments. (C) TRAFs and c-IAPs inhibit TNF-a–induced caspase-8 activity. Cell
extracts from (B) were incubated with IETD-pNA substrate. The reaction was measured as described
in Fig. 1D. (D) Coexpression of c-IAP1, c-IAP2, TRAF1, and TRAF2 restores cell resistance to
TNF-induced apoptosis in p652/2 embryonic fibroblasts. p652/2 cells were either cotransfected
(with Superfect) with pcDNA3-lacZ (0.5 mg) and one or a combination of four expression
constructs encoding c-IAP1, c-IAP2, TRAF1, and TRAF2 or with pcDNA3-lacZ and empty control
vector as labeled on the figure. The amount of transfected plasmid was performed as indicated. The
total amount of transfected plasmid DNA was kept at 4.5 mg. All experiments were performed in
six wells of a 12-well plate. After 36 hours, cells were left untreated or were treated with TNF-a
for an additional 16 hours. The attached cells were fixed with 0.5% glutaraldehyde for 15 min at
room temperature and stained with X-Gal for 6 hours or overnight. The number of blue cells in four
randomly chosen fields was counted. The results represent the average of three independent
experiments. FADD-DN, FADD-dominant negative construct.
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TRAF1 may inhibit antigen-induced apopto-
sis in a transgenic animal model (21). Also,
NF-kB can regulate c-IAP2, but this protein
is unable, on its own, to inhibit TNF-mediat-
ed apoptosis under NF-kB–null conditions
but rather provides survival function through
activating NF-kB (18). IAPs can inhibit cy-
tochrome c–induced caspase activity and the
proteolytic processing of caspase-3 (17).
Consistent with this, c-IAP1 and c-IAP2 ex-
pression alone blocked etoposide-induced
processing of caspase-3 and apoptosis in
HT1080I cells. However, although cyto-
chrome c release and caspase-3 activation
occurred in TNF-mediated apoptosis in NF-
kB–inhibited cells, the overexpression of c-
IAP1 and c-IAP2 was insufficient to inhibit
TNF-induced processing of caspase-3 and to
render cells resistant to apoptosis. Thus, TNF
and etoposide may have different caspase
requirements to efficiently kill cells, which
supports our conclusion that the recruitment
of c-IAP1 and c-IAP2 to the receptor com-
plex in response to TNF, presumably through
interactions with TRAF1 or TRAF2, is re-
quired to inhibit the apical caspase, caspase-
8. However, it is also possible that TNF-
induced killing is somehow stronger than that
induced by etoposide and requires inhibition
at the apex of the cell death pathway. These
observations underscore the importance of
the activation of TRAF1 and TRAF2 as well
as c-IAP proteins in suppressing TNF-in-
duced cell death. The fact that most cells
survive a TNF-a challenge supports the hy-
pothesis that a rapid defense mechanism in-
duced by the activation of NF-kB is required
to block death signaling at the initiating and
not at the executing stage of apoptosis be-
cause inhibiting the latter response may only
delay cell death (8, 14).
References and Notes
1. H. Hsu, H. B. Shu, M. G. Pan, D. V. Goeddel, Cell 84,
299 (1996); H. Hsu, J. Huang, H. B. Shu, V. Baichwal,
D. V. Goeddel, Immunity 4, 387 (1996); B. Z. Stanger,
P. Leder, T. H. Lee, E. Kim, B. Seed, Cell 81, 513
(1995).
2. U. Siebenlist, Annu. Rev. Cell Biol. 10, 405 (1994);
I. M. Verma, J. K. Stevensen, E. M. Schwartz, D. Van
Antwerp, S. Miyamoto, Genes Dev. 9, 2723 (1995);
P. A. Baeuerle and D. Baltimore, Cell 87, 13 (1996);
A. S. Baldwin, Annu. Rev. Immunol. 14, 649 (1996); T.
Maniatis, Science 278, 818 (1997); I. Stancovski and
D. Baltimore, Cell 91, 299 (1997); M. J. May and S.
Ghosh, Immunol. Today 19, 80 (1998).
3. M. P. Boldin, T. M. Goncharov, Y. V. Goltsev, D.
Wallach, Cell 85, 803 (1996); A. M. Chinnaiyan et al.,
J. Biol. Chem. 271, 4961 (1996); M. Muzio et al., Cell
85, 817 (1996).
4. J. P. Medema et al., EMBO J. 16, 2794 (1997); M.
Muzio, B. R. Stockwell, H. R. Stennicke, G. S. Salvesen,
V. M. Dixit, J. Biol. Chem. 273, 2926 (1998); X. Yang,
H. Y. Chang, D. Baltimore, Mol. Cell 1, 319 (1998).
5. C.-Y. Wang, M. W. Mayo, A. S. Baldwin Jr., Science
274, 784 (1996).
6. A. A. Beg and D. Baltimore, ibid., p. 782; Z.-G. Liu, H.
Hsu, D. V. Goeddel, M. Karin, Cell 87, 565 (1996); D. J.
Van Antwerp, S. J. Martin, T. Kafri, D. R. Green, I. M.
Verma, Science 274, 787 (1996); M. Wu et al., EMBO
J. 15, 4682 (1996); M. W. Mayo et al., Science 278,
1812 (1997).
7. J. Brockman et al., Mol. Cell. Biol. 15, 2809 (1995); K.
Brown, S. Gerstberger, L. Carlson, G. Franzoso, U.
Siebenlist, Science 267, 1485 (1995); E. Traenckner et
al., EMBO J. 14, 2876 (1995); B. Y. Wu, C. Woffendin, I.
Maclachlan, G. J. Nabel, J. Virol. 71, 3161 (1997); J. A.
DiDonato, M. Hayakawa, D. M. Rothwarf, E. Zandi, M.
Karin, Nature 388, 548 (1997); E. Zandi, D. M. Rothwarf,
M. Delhase, M. Hayakawa, M. Karin, Cell 91, 243 (1997);
F. Mercurio et al., Science 281, 860 (1997).
8. S. J. Martin and D. R. Green, Cell 82, 349 (1994); S.
Nagata, ibid. 88, 335 (1996); A. Fraser and G. Evan,
ibid. 85, 781 (1996); G. S. Salvesen and V. M. Dixit,
ibid. 91, 443 (1997); J. Yuan, Curr. Opin. Cell Biol. 9,
247 (1997).
9. C.-Y. Wang and A. S. Baldwin, unpublished data.
10. M. Enari, R. V. Talanian, W. W. Wong, S. Nagata,
Nature 380, 723 (1996); M. Tewari et al., Cell 81, 801
(1995); D. Xue, S. Shaham, H. R. Horvitz, Genes Dev.
10, 1073 (1996).
11. Y. A. Lazebnik, S. H. Kaufmann, S. Desnoyers, G. G.
Poirier, W. C. Earnshaw, Nature 371, 346 (1994);
D. W. Nicholson and N. A. Thornberry, Trends Bio-
chem. Sci. 22, 299 (1997).
12. X. Liu, H. Zou, C. Slaughter, X. Wang, Cell 89, 175
(1997); M. Enari et al., Nature 391, 43 (1998).
13. X. Liu, C. N. Kim, J. Yang, R. Jemmerson, X. Wang, Cell
86, 147 (1996).
14. M. O. Hengartner and H. R. Horvitz, Curr. Opin.
Genet. Dev. 4, 581 (1994); R. M. Kluck, E. Bossy-
Wetzel, D. R. Green, D. D. Newmeyer, Science 275,
1132 (1997); S. J. Korsmeyer, Trends Genet. 11, 101
(1995); J. C. Reed, Nature 387, 773 (1997); J. Yang et
al., Science 275, 1129 (1997).
15. R. J. Clem and L. K. Miller, Mol. Cell. Biol. 14, 5212
(1994); C. S. Duckett et al., EMBO J. 15, 2685 (1996);
P. Liston et al., Nature 379, 349 (1996); A. G. Uren, M.
Pakusch, C. J. Hawkins, K. L. Puls, D. L. Vaux, Proc.
Natl. Acad. Sci. U.S.A. 93, 4974 (1996).
16. H. Shu, M. Takeuchi, D. V. Goeddel, Proc. Natl. Acad.
Sci. U.S.A. 93, 13973 (1996).
17. N. Roy, Q. L. Deveraux, R. Takahashi, G. S. Salvesen,
J. C. Reed, EMBO J. 16, 6914 (1997).
18. Z. L. Chu et al., Proc. Natl. Acad. Sci. U.S.A. 94, 10057
(1997).
19. M. You, P.-T. Ku, R. Hrdlickova, H. Bose, Mol. Cell.
Biol. 17, 7328 (1997).
20. W. Yeh et al., Immunity 7, 715 (1997); S. Y. Lee et al.,
ibid., p. 703.
21. D. E. Speiser et al., J. Exp. Med. 185, 1777 (1997).
22. We thank X. Wang for the DFF-45 polyclonal anti-
body, A. Beg for the p652/2 fibroblasts, V. Dixit for
expression vectors, helpful comments, and sugges-
tions, and P. Liston and C. Duckett for advice. Support
was provided by NIH grants AI35098 and CA73756
(to A.S.B.), NIH grant CA 75080 (to A.S.B. and
M.W.M.), an NIH postdoctoral fellowship (to
M.W.M.), an NIH Dentist Scientist Award, the Uni-
versity of North Carolina School of Dentistry Junior
Faculty Starting Fund, and NIH grant DE12823 (to
C.-Y.W ).
26 March 1998; accepted 4 August 1998
Biological Action of Leptin as an
Angiogenic Factor
M. Rocı́o Sierra-Honigmann,* Anjali K. Nath, Chiaki Murakami,
Guillermo Garcı́a-Cardeña,† Andreas Papapetropoulos,
William C. Sessa, Lisa A. Madge, Jeffrey S. Schechner,
Michael B. Schwabb, Peter J. Polverini, Jaime R. Flores-Riveros‡
Leptin is a hormone that regulates food intake, and its receptor (OB-Rb) is
expressed primarily in the hypothalamus. Here, it is shown that OB-Rb is also
expressed in human vasculature and in primary cultures of human endothelial
cells. In vitro and in vivo assays revealed that leptin has angiogenic activity. In
vivo, leptin induced neovascularization in corneas from normal rats but not in
corneas from fa/fa Zucker rats, which lack functional leptin receptors. These
observations indicate that the vascular endothelium is a target for leptin and
suggest a physiological mechanism whereby leptin-induced angiogenesis may
facilitate increased energy expenditure.
Leptin, a circulating hormone secreted by
adipocytes, influences body weight ho-
meostasis through effects on food intake and
energy expenditure (1). It also modulates oth-
er physiological actions, including lipid me-
tabolism, hematopoiesis, pancreatic b cell
function, ovarian function, and thermogene-
sis (2). Despite this multiplicity of biological
effects in extraneural tissues, the leptin recep-
tor is expressed predominantly in the hypo-
thalamus (3). Alternative splicing of a single
transcript encoded by the db gene produces
several variants of the leptin receptor, includ-
ing a transmembrane full-length, long form
(OB-Rb) expressed at high levels in discrete
hypothalamic regions (4). The OB-Rb form
has a cytoplasmic domain that transduces the
leptin signal through the Jak-STAT pathway
(5, 6).
The discovery of leptin and its receptor
strongly supports the hypothesis that adipose
tissue mass is regulated by a hormone that is
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